MCRB - セレス・セラピュ―ティックス (Seres Therapeutics Inc.) セレス・セラピュ―ティックス

 MCRBのチャート


 MCRBの企業情報

symbol MCRB
会社名 Seres Therapeutics Inc (セレス・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セレス・セラピューティクス(Seres Therapeutics Inc.)はマイクロバイオーム治療プラットフォーム会社である。同社はエコビオティック微生物治療薬という生物薬の開発に従事する。同社の医薬品は、ジビオティック微生物の機能を修復することによって健康を回復するように設計される。同社は、結腸微生物の不全症を治療するエコビオティック・マイクロビオム治療法を開発するために、その微生物治療プラットフォームを実施する。SER-109はクロストリジウム・ディフィシル感染症(CDI)のさらなる再発を防ぐために設計されたリード製品候補である。同社は、主要なCDIの初期再発を防ぐためのSER-262、潰瘍性大腸炎を含む炎症性腸疾患(IBD)を治療するためのSER-287およびSER-301、並びに腸内細菌病原体を治療するためのSER-155を含む他の製品候補を開発する。   セレス・セラピュ―ティックスは米国のマイクロバイオ―ム治療法プラットフォ―ム開発企業。生物学的薬剤を開発し、腸内の微生物群であるマイクロバイオ―ムの機能を元に戻す治療法に取り組む。クロストリジウム・ディフィシル感染症の再発を防ぐSER-109、潰瘍性大腸炎を治療するSER-287、抗生物質抵抗性バクテリアを処理するSER-155を開発する。   Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
本社所在地 200 Sidney Street - 4th Floor Cambridge MA 02139 USA
代表者氏名 Roger Pomerantz ロジャー・ポメラント
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 617-945-9626
設立年月日 40452
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 138人
url www.serestherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/mcrb
adr_tso
EBITDA EBITDA(百万ドル) -85.82700
終値(lastsale) 6.77
時価総額(marketcap) 276186638.51
時価総額 時価総額(百万ドル) 266.39570
売上高 売上高(百万ドル) 34.65400
企業価値(EV) 企業価値(EV)(百万ドル) 170.32970
当期純利益 当期純利益(百万ドル) -91.59400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Seres Therapeutics Inc revenues increased 42% to $8.6M. Net loss increased 4% to $55.7M. Revenues reflect Collaboration revenue - related party increase of 33% to $8M. Higher net loss reflects Research and development expenses increase of 10% to $43.3M (expense) Interest income decrease of 75% to $349K (income) General and administrative expenses increase of 6% to $13.1M (expense).

 MCRBのテクニカル分析


 MCRBのニュース

   Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors  2019/12/16 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics announces the appointment of Stephen Berenson as Chairman of its Board of Directors.
   Human Microbiome World Markets to 2023, Featuring Chr. Hansen, Enterome Bioscience, Seres Therapeutics, and Viome  2019/11/25 10:15:00 PR Newswire
DUBLIN, Nov. 25, 2019 /PRNewswire/ -- The "Growth Opportunities in Human Microbiome Market, Forecast to 2023" report has been added to ResearchAndMarkets.com's offering. This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive…
   Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference  2019/11/14 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019.
   Cowen Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)  2019/11/07 23:20:43 Modern Readers
Cowen reaffirmed their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note published on Monday morning, AnalystRatings.com reports. Several other research firms have also recently commented on MCRB. ValuEngine raised shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. BidaskClub cut […]
   BidaskClub Upgrades Seres Therapeutics (NASDAQ:MCRB) to Buy  2019/11/07 16:22:59 Modern Readers
Seres Therapeutics (NASDAQ:MCRB) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, BidAskClub reports. Several other research firms have also recently weighed in on MCRB. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on […]
   Seres Therapeutics (MCRB) CEO Eric Shaff on Q1 2019 Results - Earnings Call Transcript  2019-05-06
Seres Therapeutics (MCRB) Q1 2019 Earnings Conference Call May 2, 2019 08:30 ET Company Participants Carlo Tanzi - VP, IR & Corporate Communications Eric Shaff - President & CEO Kevin Horgan - Chief Medical Officer Matthew Henn - Chief Scientific Officer Conference C…
   Seres Therapeutics misses by $0.13, misses on revenue  2019-05-02
Seres Therapeutics (NASDAQ: MCRB ): Q1 GAAP EPS of -$0.59 misses by $0.13 . More news on: Seres Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more …
   Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update  2019-05-02 Business Wire
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs - SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed b…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレス・セラピュ―ティックス MCRB Seres Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)